---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-22-023044"
form_type: "8-K"
ticker: "LNSR"
cik: "0001320350"
company_name: "LENSAR, Inc."
filed_at: "2022-06-13T23:59:59+00:00"
generated_at: "2026-06-25T02:16:06.532736+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# LENSAR receives FDA 510(k) clearance for ALLY Adaptive Cataract Treatment System

## Summary
- FDA 510(k) clearance received on June 9, 2022 for next-generation ALLY system.
- ALLY is first FDA-cleared platform for femtosecond-laser cataract surgery in a single sterile environment.
- Initial controlled launch planned for Q3 2022; wider availability targeted in 2023.
- Over 125 surgeons experienced ALLY during live demonstrations at ASRS and company office.

## SEC filing metadata
- accession: 0001564590-22-023044
- form_type: 8-K
- ticker: LNSR
- cik: 0001320350
- company_name: LENSAR, Inc.
- filed_at: 2022-06-13T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1320350/000156459022023044/0001564590-22-023044-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1320350/000156459022023044/lnsr-8k_20220609.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-22-023044
- JSON: https://secwatch.observer/filing/0001564590-22-023044.json
- Plain text: https://secwatch.observer/filing/0001564590-22-023044.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.